Gentamicin is named as an intervention in 6 current clinical trials in our France, Israel, Norway and Canada registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Western Galilee Hospital-Nahariya (2). The most-studied condition is Acute Mesenteric Ischemia. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Gentamicin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)
2026-526131-20-00 · Bacterial Infections and Mycoses
|
Phase 4 | Authorised | Region Hovedstaden | Denmark |
|
FOSFOLD - Fosfomycin trometamol compared with another active antibiotic relay therapy for the treatment of acute Escherichia coli pyelonephritis in elderly women: a randomized, multicenter, non-inferiority trial
2025-521663-13-00 · Female Urogenital Diseases and Pregnancy Complications
|
Phase 3 | Authorised | Assistance Publique Hopitaux De Paris | France |
|
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
2026-526149-91-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Friedrich-Schiller-Universitaet Jena | Germany |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
7 single-substance products containing Gentamicin on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Western Galilee Hospital-Nahariya | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| University Hospital, Toulouse | 1 |
| University Hospital, Akershus | 1 |
| Sharp HealthCare | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 2 | 1 |
| Clinical trials in Israel | 2 | 2 |
| Clinical trials in Norway | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
6 current trials in our France, Israel, Norway and Canada registers name Gentamicin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 6 trials are recruiting: 1 with sites in France, 2 with sites in Israel and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Western Galilee Hospital-Nahariya (2), Assistance Publique - Hôpitaux de Paris (1), University Hospital, Toulouse (1) and University Hospital, Akershus (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 7 single-substance products containing Gentamicin, for example Gentamicin 40 mg/mL solution for injection/infusion (Noridem Enterprises Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 2 entries for Gentamicin: 2 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Gentamicin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gentamicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gentamicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.